his.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Plasminogen binding inhibitors demonstrate unwanted activities on GABAA and glycine receptors in human iPSC derived neurons
AstraZeneca, Mölndal, Sweden.
AstraZeneca, Mölndal, Sweden / Karolinska Institutet, Stockholm, Sweden.
Emeriti Bio, AZ Bioventure Hub, Mölndal, Sweden.
Emeriti Bio, AZ Bioventure Hub, Mölndal, Sweden.
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: Neuroscience Letters, ISSN 0304-3940, E-ISSN 1872-7972, Vol. 681, s. 37-43, artikel-id S0304-3940(18)30351-3Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Plasminogen binding inhibitors (PBIs) reduce the risk of bleeding in hemorrhagic conditions. However, generic PBIs are also associated with an increased risk of seizures, an adverse effect linked to unwanted activities towards inhibitory neuronal receptors. Development of novel PBIs serve to remove compounds with such properties, but progress is limited by a lack of higher throughput methods with human translatability. Herein we apply human induced pluripotent stem cell (hiPSC) derived neurons in combination with dynamic mass redistribution (DMR) technology to demonstrate robust and reproducible modulation of both GABAA and glycine receptors. These cells respond to GABA (EC50 0.33 ± 0.18 μM), glycine (EC50 11.0 ± 3.7 μM) and additional ligands in line with previous reports from patch clamp technologies. Additionally, we identify and characterize a competitive antagonistic behavior of the prototype inhibitor and drug tranexamic acid (TXA). Finally, we demonstrate proof of concept for effective counter-screening of lead series compounds towards unwanted GABAAreceptor activities. No activity was observed for a previously identified PBI candidate drug, AZD6564, whereas a discontinued analog, AZ13267257, could be characterized as a potent GABAA receptor agonist.

Ort, förlag, år, upplaga, sidor
Elsevier , 2018. Vol. 681, s. 37-43, artikel-id S0304-3940(18)30351-3
Nyckelord [en]
Drug screening, Dynamic mass redistribution, GABA(A) receptor, Glycine receptor, Pharmacology, hiPSC derived neurons
Nationell ämneskategori
Cellbiologi
Forskningsämne
Bioinformatik; INF502 Biomarkörer
Identifikatorer
URN: urn:nbn:se:his:diva-15263DOI: 10.1016/j.neulet.2018.05.018ISI: 000442191200008PubMedID: 29758302Scopus ID: 2-s2.0-85047397711OAI: oai:DiVA.org:his-15263DiVA, id: diva2:1212838
Tillgänglig från: 2018-06-04 Skapad: 2018-06-04 Senast uppdaterad: 2019-11-20Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Delsing, Louise

Sök vidare i DiVA

Av författaren/redaktören
Delsing, Louise
Av organisationen
Institutionen för biovetenskapForskningscentrum för Systembiologi
I samma tidskrift
Neuroscience Letters
Cellbiologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 242 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf